| Medical and Health Sciences | Lifetime | 110 | US 61 | 99.99 |
| Medical and Health Sciences | 2021-2025 | 14 | US 8 | 100.00 |
| Cardiology and Cardiovascular Medicine | Lifetime | 14 | US 11 | 99.99 |
| Endocrinology, Diabetes and Metabolism | Lifetime | 90 | US 50 | 99.72 |
| Pulmonary and Respiratory Medicine | Lifetime | 955 | US 490 | 98.42 |
| Radiology, Nuclear Medicine and Imaging | Lifetime | 758 | US 414 | 97.99 |
| Nephrology | Lifetime | 596 | US 283 | 92.95 |
| Cardiology and Cardiovascular Medicine | 2021-2025 | 3 | US 2 | 99.99 |
| Endocrinology, Diabetes and Metabolism | 2021-2025 | 10 | US 7 | 99.93 |
| Molecular Biology | 2021-2025 | 664 | US 190 | 96.40 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 390 | US 124 | 96.00 |
| Epidemiology | 2021-2025 | 511 | US 169 | 95.35 |
| Surgery | 2021-2025 | 642 | US 244 | 94.44 |
| Cardiovascular Function and Risk Factors | Lifetime | 4 | US 4 | 99.99 |
| Heart Failure Treatment and Management | Lifetime | 5 | US 5 | 99.98 |
| Cardiac pacing and defibrillation studies | Lifetime | 10 | US 8 | 99.94 |
| Diabetes Treatment and Management | Lifetime | 19 | US 11 | 99.85 |
| Potassium and Related Disorders | Lifetime | 5 | US 5 | 99.85 |
| Hormonal Regulation and Hypertension | Lifetime | 57 | US 28 | 99.58 |
| Blood Pressure and Hypertension Studies | Lifetime | 117 | US 51 | 99.55 |
| COVID-19 Clinical Research Studies | Lifetime | 194 | US 51 | 99.03 |
| Cardiac Imaging and Diagnostics | Lifetime | 208 | US 114 | 99.63 |
| Cardiac electrophysiology and arrhythmias | Lifetime | 174 | US 94 | 99.45 |
| Amyloidosis: Diagnosis, Treatment, Outcomes | Lifetime | 66 | US 40 | 98.86 |
| Cardiac Structural Anomalies and Repair | Lifetime | 209 | US 143 | 99.29 |
| Electrolyte and hormonal disorders | Lifetime | 111 | US 51 | 98.60 |
| Ultrasound in Clinical Applications | Lifetime | 95 | US 44 | 98.32 |
| Cardiac Arrhythmias and Treatments | Lifetime | 358 | US 184 | 99.00 |
| COVID-19 and healthcare impacts | Lifetime | 224 | US 87 | 96.65 |
| Long-Term Effects of COVID-19 | Lifetime | 344 | US 83 | 97.20 |
| Atrial Fibrillation Management and Outcomes | Lifetime | 475 | US 201 | 98.81 |
| Cardiomyopathy and Myosin Studies | Lifetime | 275 | US 145 | 98.40 |
| Erythropoietin and Anemia Treatment | Lifetime | 102 | US 46 | 98.07 |
| Pulmonary Hypertension Research and Treatments | Lifetime | 402 | US 192 | 97.97 |
| Acute Myocardial Infarction Research | Lifetime | 536 | US 241 | 98.39 |
| Pancreatic function and diabetes | Lifetime | 902 | US 377 | 97.74 |
| Heart rate and cardiovascular health | Lifetime | 32 | US 10 | 97.81 |
| Cardiovascular Health and Disease Prevention | Lifetime | 658 | US 251 | 97.21 |
| Cardiovascular Effects of Exercise | Lifetime | 630 | US 268 | 96.68 |
| Chronic Kidney Disease and Diabetes | Lifetime | 609 | US 254 | 96.77 |
| Inflammatory mediators and NSAID effects | Lifetime | 851 | US 372 | 95.74 |
| Cardiovascular Disease and Adiposity | Lifetime | 952 | US 427 | 95.71 |
| Renin-Angiotensin System Studies | Lifetime | 473 | US 187 | 95.87 |
| Cardiovascular Health and Risk Factors | Lifetime | 843 | US 432 | 90.63 |
| Advanced Causal Inference Techniques | Lifetime | 596 | US 368 | 88.25 |
| Cardiovascular Function and Risk Factors | 2021-2025 | 2 | US 2 | 99.98 |
| Heart Failure Treatment and Management | 2021-2025 | 3 | US 3 | 99.97 |
| Cardiac pacing and defibrillation studies | 2021-2025 | 10 | US 2 | 99.80 |
| Diabetes Treatment and Management | 2021-2025 | 13 | US 9 | 99.90 |
| Hormonal Regulation and Hypertension | 2021-2025 | 7 | US 5 | 99.66 |
| Electrolyte and hormonal disorders | 2021-2025 | 6 | US 4 | 98.46 |
| Pancreatic function and diabetes | 2021-2025 | 41 | US 28 | 98.75 |
| Amyloidosis: Diagnosis, Treatment, Outcomes | 2021-2025 | 32 | US 15 | 98.51 |
| Cardiomyopathy and Myosin Studies | 2021-2025 | 54 | US 23 | 98.37 |
| Potassium and Related Disorders | 2021-2025 | 12 | US 8 | 99.14 |
| Atrial Fibrillation Management and Outcomes | 2021-2025 | 267 | US 76 | 98.08 |
| Cardiac Imaging and Diagnostics | 2021-2025 | 419 | US 132 | 97.13 |
| Blood Pressure and Hypertension Studies | 2021-2025 | 228 | US 87 | 96.08 |
| Influenza Virus Research Studies | 2021-2025 | 302 | US 122 | 93.33 |
| Health Systems, Economic Evaluations, Quality of Life | 2021-2025 | 903 | US 295 | 93.38 |
| Cardiac electrophysiology and arrhythmias | 2021-2025 | 458 | US 113 | 94.16 |
| Parathyroid Disorders and Treatments | 2021-2025 | 215 | US 61 | 92.89 |
| Erythropoietin and Anemia Treatment | 2021-2025 | 67 | US 24 | 92.75 |
| Metabolism, Diabetes, and Cancer | 2021-2025 | 356 | US 92 | 89.99 |
| Cardiac Structural Anomalies and Repair | 2021-2025 | 837 | US 369 | 91.67 |
| Acute Myocardial Infarction Research | 2021-2025 | 821 | US 196 | 90.94 |
| Pulmonary Hypertension Research and Treatments | 2021-2025 | 667 | US 220 | 88.52 |
| Cardiovascular Effects of Exercise | 2021-2025 | 618 | US 173 | 86.66 |
| Heart rate and cardiovascular health | 2021-2025 | 25 | US 12 | 82.42 |
| Dialysis and Renal Disease Management | 2021-2025 | 916 | US 199 | 86.60 |
| Cardiac Health and Mental Health | 2021-2025 | 742 | US 226 | 84.04 |
| Viral Infections and Immunology Research | 2021-2025 | 929 | US 238 | 82.21 |
| Statistical Methods in Clinical Trials | 2021-2025 | 653 | US 273 | 74.37 |
| Advanced Causal Inference Techniques | 2021-2025 | 465 | US 251 | 71.58 |
| Ion Transport and Channel Regulation | 2021-2025 | 394 | US 122 | 67.80 |
| Apelin-related biomedical research | 2021-2025 | 481 | US 76 | 50.67 |
| Signaling Pathways in Disease | 2021-2025 | 974 | US 225 | 45.03 |
| Protein Kinase Regulation and GTPase Signaling | 2021-2025 | 913 | US 378 | 37.27 |
